

Review Article

Preeclampsia: Where do we stand for an Early Diagnosis?

Gatien AG Lokossou^{1,2*}, Caroline Toudic³, Evelyne J. Lozes², Lucien Davito¹, Amirath A. Badarou¹, Rene X. Pérrin¹, and Benoit Barbeau³

¹Hospital and University Hospital-Mother and Child of the Lagoon (CHU-MEL), Benin

²Aquomie Calavi Polytechnic School, Benin

³Department of Biological Sciences / BioMed Research Center, University of Quebec in Montreal, Canada

*Corresponding author

Gatien AG Lokossou, Hospital and University Hospital-Mother and Child of the Lagoon (CHU-MEL), Benin, 01 BP: 419, Porto-Novo, Republic of Benin, Tel: 0022964757648; Email: gatien.lokossou@epac.uac.bj

Submitted: 05 October 2017

Accepted: 14 February 2018

Published: 20 February 2018

ISSN: 2333-6439

Copyright

© 2018 Lokossou et al.

OPEN ACCESS

Keywords

• Biomarkers; Pregnancy; Preeclampsia; Diagnosis

Abstract

Preeclampsia represents a danger to nearly 10 million pregnant women worldwide. This gestational pathology has very important consequences for preeclamptic (PE) women but also for newborns. To date, no early diagnostic tools are available for PE, resulting from the difficulties to identify the originating cause of this disease. However, researchers and clinicians are actively working on the identification of a biomarker acceptable to all. This is a challenging work as this biomarker must be able to identify pregnant women at risk of developing PE as early as possible during their pregnancy, in a non-invasive way and at low costs. The identification of early PE biomarkers will allow a better management of pregnant women at risk for PE or suspected for PE, and reduce maternal and child morbidity and mortality associated with this disease. Several molecules and genes have been identified as potential candidates over the years. However, not one of these has been unanimously accepted. This review will present the current state of research regarding the potentially best PE markers or combination of markers identified as of now.

ABBREVIATIONS

PE: Preeclampsia; CTLA4: Cytotoxic T-Lymphocyte-Associated protein 4; F2: the coagulation factor II; FV: the coagulation factor V; SERPINE: Serine Peptidase Inhibitor 1; LEPR: Leptin Receptor Gene; NAD(P)H: Methylene tetrahydrofolate Reductase; WG: Weeks of Gestation; hCG: human Chorionic Gonadotropin; hPL: human Placental Lactogen; PIGF: Placental Growth Factor; VEGF: Endothelial Growth Factor; sFLT1: Soluble fms-Like Tyrosine Kinase 1; LXR α : Liver X Receptor Alpha; PAPP-A: Pregnant-Associated Plasma Protein A; PP13: Placenta Protein 13; sTWEAK: soluble TNF-Like Weak Inducer of Apoptosis; SDE: Serum Derived-Exosomes; CD: Cluster of Differentiation; NGAL: Neutrophil Gelatinase-Associated Lipocalin; MAP: Mean Arterial Pressure

INTRODUCTION

Preeclampsia (PE) is a serious placental disorder characterized by the onset of hypertension and the presence of either proteinuria or other severe features during pregnancy in previously normotensive woman [1-3]. In the absence of medical care, this obstetric disorder can lead to multiorgan dysfunction, eclamptic crisis and maternal death [4-6] and is thereby one of the important causes of maternal and perinatal morbidity and mortality. PE affects 2 to 10% of pregnancies and occurs more frequently in low-income countries [7-9]. The clinical symptoms appear after 20 weeks of gestation and can in fact be detected as late as 4-12 weeks postpartum [10-13]. Risks are also important for the fetus and newborn. These include increased morbidity and mortality, associated with uterine growth retardation and

iatrogenic premature childbirth [4,14]. Each year, 10 million pregnant women develop PE around the world. Worldwide, about 100,000 pregnant women and 500,000 babies die each year from preeclampsia. 99% of these mortalities occur in low and middle income countries [15]. Management of PE is limited to treatment of symptoms and in severe cases, require early childbirth to prevent deterioration of the condition of the mother and the fetus. Early diagnosis of PE would be helpful for careful monitoring of pregnant women and preventive strategies. Research efforts in the last ten years have improved our understanding of the pathophysiology of PE. Indeed, it is now accepted that this obstetrical disorder is the consequence of poor placentation [16-23]. Therefore, important efforts have been made for the identification of biomarkers or risk factors associated to PE. This has further led to the development of new algorithms combining clinical risk factors with biomarkers for a good prediction of PE [24-29].

Since PE is a multifactorial pathology, a single marker is likely not to be sufficient in terms of diagnostic value [30]. To improve early PE diagnosis, researchers are thus seeking to develop multiparametric models including biochemical, molecular and genetic markers, body-mass index, mean arterial blood pressure, presence of nulliparity or previous preeclampsia and Doppler parameters [31-36]. Markers of fetal, placental or renal origin and specific markers of oxidative stress have been included in these studies [37].

MOLECULAR AND GENETIC MARKERS

Although important discoveries have been made with

respect to PE and its origins, the pathogenesis of this disorder still remains mostly obscure. Meta-analysis has been used to identify specific genes that are associated to preeclampsia or severe preeclampsia. Among these, the Angiotensin-Converting Enzyme, Cytotoxic T-Lymphocyte-Associated protein 4 (CTLA4), the coagulation factor II (F2, also known as prothrombin), the coagulation factor V (FV), Lipoprotein lipase and SERPINE Serine Peptidase Inhibitor 1 genes have been shown to be associated with preeclampsia [38]. Furthermore, Fong et al., showed that coagulation factor V gene (proaccelerin) polymorphism, leptin receptor gene (LEPR) polymorphism, mutated coagulation factor II (thrombin) and the thrombophilic gene group polymorphism (including F2, FV and Methylenetetrahydrofolate reductase (NAD(P)H) genes were associated to severe preeclampsia [39].

Several studies have demonstrated that cell-free DNA could also potentially be used as PE markers [40-44]. But these studies are very heterogeneous and it is difficult to make a precise conclusion about the statistical and clinical relevance of these findings. Recently, the search for PE biomarkers and therapeutic molecules led to the identification of several microRNAs (miRNAs), which expression are dysregulated during PE [45-51]. miRNA are noncoding RNAs that modulate the expression of various target genes through complementary annealing to targeted mRNA. Interestingly, these miRNAs are detected in maternal serum. In 2015, using qRT-PCR, Murphy et al., have shown an increase in levels of miR-98, miR-222, miR-210, miR-155, miR-296, miR-181a, and miR-29b in the blood of severe PE pregnant women [51]. More recently, Zhang et al., showed a decrease of miR-942 prior to 20 weeks of gestation (WG) in the plasma of PE women [52]. This recent result is interesting as this reduction in miRNA abundance was observed before 20 WG unlike other identified miRNAs, where the variation in levels were detected at childbirth. Combined together, these studies on miRNAs show promising advances in the identification of plasma PE biomarkers but more studies are needed to confirm that miRNAs can be used as early PE marker.

PLACENTAL RELATED BIOMARKERS

Preeclampsia is characterized by the onset of hypertension and proteinuria during pregnancy [53] but the factor or combination of factors responsible for these disturbances is unknown. However, a relevant marker of PE should be linked to these symptoms. It is undeniable that this marker, once identified and validated, will allow better surveillance and pharmacological intervention involving a low-dose of aspirin or calcium supplementation to improve PE outcome [54-56]. Since PE is intrinsically related to the placenta [16-23,57], a good marker could be directly related to its structure and/or function. This indispensable organ is composed of various cell types, which include extravillous and villous cytotrophoblasts. Villous cytotrophoblasts have the ability to differentiate into a multinucleated cellular barrier called the syncytiotrophoblast that covers the chorionic villi. The resulting overlaying structure is in direct contact with maternal blood and plays a crucial role for nutrient and hormone exchanges between the mother and the fetus as well as producing important soluble factors, such as human chorionic gonadotropin (hCG) and human placental lactogen (hPL) [58] and pro- and anti-angiogenic factors [59-61].

Thus, a defect in the formation of the placenta would result in a defect in the production of these soluble factors.

Ideally, this placenta-associated biomarker must be detectable before 20 weeks of gestation (WG) in order for clinicians to act early in pregnancy. Several biomarkers associated with the placenta have been identified and are considered promising. Among them is the Placental Growth Factor (PlGF), a member of the vascular endothelial growth factor (VEGF) family that plays a role in angiogenesis and trophoblastic invasion [60,62]. Indeed, the studies of Tsiakkas et al. (2015), have shown low PlGF plasma levels in PE pregnancies before 13 weeks of gestation [63,64]. Another promising marker is the soluble fms-Like Tyrosine Kinase 1 (sFLT1), a soluble VEGF receptor and antiangiogenic protein involved in inhibition of VEGF and PlGF signaling. It is known that plasma levels of sFLT1 are significantly higher in PE compared to normal pregnancies [65] and several studies suggest the use of sFLT1 levels as a biomarker of PE and severe PE [66-68].

Decrease in plasma PlGF levels during PE is thought to be due to higher release of sFLT1 from the placenta [66] which binds to circulating PlGF [69,70]. Combining both sFLT1 and PlGF plasma levels could also help predict the occurrence of PE in pregnant women. Indeed, several studies showed that the sFLT1/PlGF ratio was significantly higher in women that were diagnosed with PE or that later developed PE compared to normal pregnancies [69,71,72]. The use of sFLT1 and PlGF as PE markers is interesting as both proteins are placental-derived, and their expression levels in maternal serum presumably reflect impaired placentation [25,31,63,66].

As PE is associated with several maternal factors, including obesity, it is important to evaluate the accuracy of PE biomarkers in different populations of pregnant women. A thorough analysis of the use of PlGF as a biomarker in obese pregnant women showed lower plasma PlGF levels in early pregnancy associated with the later development of PE in obese women but not in women with normal body-mass index [73]. This study shows that obesity influences PlGF plasma levels and consequently that this biomarker might rather be specific to certain populations of pregnant women. PlGF has further been associated to PE and severe PE in pregnant women with established hypertension and chronic kidney disease. In several studies, the authors have shown that PlGF decreased several weeks before the onset of PE symptoms [66,74-76]. PlGF appears to be an early biomarkers but might be more related to maternal risk factors-associated PE and its single use as biomarker might not identify all PE cases [25,76-78].

It has also been suggested that abnormal liver X receptor alpha (LXR α) and endoglin might play significant roles in the development of PE [79-83]. Studies showed that LXR α inhibited cholesterol transport, human chorionic gonadotropin and trophoblast invasion [84], while endoglin, a trans-membrane glycoprotein expressed on syncytiotrophoblast and invasive cytotrophoblast, is involved in placental trophoblast differentiation and uterus invasion [85]. Endoglin is a co-receptor for transforming growth factor- β 1 and 3 [82] and is a direct target of LXR α on human syncytiotrophoblast [79]. According to the role associated to LXR α and endoglin in placental trophoblast

differentiation, Wang et al., have tested the relationship between LXR α and endoglin levels and occurrence of preeclampsia. In their study, they showed that elevated levels of LXR α and endoglin was associated with PE pathogenesis and development and have suggested that LXR α and endoglin could be used as PE biomarker. However, it is important to note that the decrease in levels of these markers was observed at 36 weeks of pregnancy [86].

Ongoing studies have shown that Pregnant-Associated Plasma Protein A (PAPP-A), a highly glycosylated protein produced by developing trophoblast cells [87], and Placenta Protein 13 (PP13), a member of the galectin super-family (known as galectin 13 and β -galactoside-specific lectins [88] could also be potential markers to predict PE [35,89-91]. Unfortunately, these preeclampsia biomarkers were shown to have extremely variable diagnostic value [35,92-97]. In a pilot clinical study, Kayaoglu et al. (2016), showed that soluble TNF-Like Weak Inducer of Apoptosis (sTWEAK) could represent a new potential marker for preeclampsia. Indeed, they have shown that sTWEAK levels decreased in patients with PE, although this decrease was detected at 20 WG compared to normal pregnant women [98]. Further work is needed to assess the diagnostic value of this potential PE biomarker at earlier points during pregnancy.

RETROVIRAL-DERIVED BIOMARKERS

As indicated above, several scientific studies have shown that preeclampsia is the consequence of a defect in placenta formation [16-18,20-23,57], followed by an exaggerated systemic inflammatory response [30,99-112]. Syncytin-2 is a protein derived from a human endogenous retrovirus sequence. We have recently demonstrated that syncytin-2 is an important player in the formation of the placenta [58,113]. It has also been strongly suggested that syncytin-2 could contribute in generating the immunosuppressive environment needed for proper fetal development [111,112]. In addition to its role in maternal-fetal exchange, the placenta produces microvesicles called exosomes that seem to be endowed with immunosuppressive properties [58,114]. We and others have recently shown that syncytin-2 is present on the surface of these exosomes and could contribute to maternal-fetal immune tolerance [112,115]. Our recently published results showed a lower incorporation of syncytin-2 on the surface of serum-derived exosomes of women with preeclampsia [115].

Based on these findings, we have recently initiated a new study, in which 450 pregnant women were enrolled at Cotonou, Benin, and have monitored the incorporation of syncytin-2 in their serum derived-exosomes (SDE) until 25 weeks of gestation. This ongoing study shows that the mean ratio of Sync-2/CD63 (CD63 being an exosome marker) in women who developed preeclampsia was significantly lower compared to women without preeclampsia between 7 and 13 weeks of pregnancy (Lokossou et al., unpublished data). Recent results from our team and others thus concur to the possibility that this protein could be a promising PE marker and could be ideal for early diagnosis.

OTHER BIOMARKERS

Other predictive models for estimating individualized risk for onset PE are currently being explored. Among these, Karampas

et al., have shown that the combination of Neutrophil Gelatinase-associated Lipocalin (NGAL), maternal clinical characteristics and Doppler parameters in the first and/or second trimester can be used to identify an important number of PE pregnancies [116]. As an alternative, Chang et al. (2016), proposed a new predictive model for early-onset PE through quantification of maternal serum levels of PAPP-A, PlGF, PP13 and soluble endoglin, measurement of mean arterial pressure (MAP) and analyses of uterine artery Doppler [117]. It is hoped that the best algorithm will eventually detect a larger number of pregnant women at risk of developing PE and limit the number of false positives. Other biomarkers, such as syncytin-2, will thereby be interesting addition to these models to potentially improve their diagnostic value, especially at early time points of pregnancy.

CONCLUSION

Significant progress has been made in the understanding of the pathophysiology of preeclampsia and suggests that the best prediction for PE development during pregnancy may be a combination of specific parameters. Given the heterogeneous nature of this obstetric placenta-derived disorder, the chosen biomarkers should be related to the physiopathology of the placenta. It is also important to take into account the capacities of low-income countries to appropriately conduct early diagnosis of PE and consequently diagnostic tools will have to be easy-to-use and bear reasonable costs. Indeed, it would be very difficult to consider the use of molecular and genetic markers for the early diagnosis of preeclampsia in middle and low income countries. In addition, most of these genetic markers were tested in small samples. Their representativeness can therefore be questioned. For this, serum biomarkers derived from the placenta such as PlGF, sFLT1 and syncytin-2 may be good tools for early diagnosis of preeclampsia. However, PlGF and sFlt do not seem to allow a diagnosis before 20 which is not the case of syncytin-2 which could be used between 7 and 13 weeks for early diagnosis of PE.

Future studies should permit to assess new PE markers for early diagnosis and provide such a clinical tools, which will greatly improve care of pregnant women showing predisposition to PE development.

ACKNOWLEDGEMENTS

We would like to acknowledge the International Development Research Centre (IDRC) and The World Academy of Sciences (TWAS) for funding the study carried out in Benin one the incorporation of syncytin-2 in pregnant women serum derived-exosomes (SDE) until 25 weeks of gestation

REFERENCES

1. Pauli JM, Repke JT. Preeclampsia: Short-term and Long-term Implications. *Obstet Gynecol Clin North Am.* 2015; 42: 299-313.
2. Say L, Chou D, Gemmill A, Tunçalp Ö, Moller AB, Daniels J, et al. Global causes of maternal death: a WHO systematic analysis. *Lancet Glob Health.* 2014; 2: 323-333.
3. Khan KS, Wojdyla D, Say L, Gülmezoglu AM, Van Look PF. WHO analysis of causes of maternal death: a systematic review. *Lancet.* 2006; 367: 1066-1074.
4. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. *Lancet.* 2005; 365: 785-799.

5. Radha Bai Prabhu T1. Serious Visual (Ocular) Complications in Pre-eclampsia and Eclampsia. *J Obstet Gynaecol India*. 2017; 67: 343-348.
6. Lee JY, Kim YL, Jeong JE, Ahn JW. Prediction of pregnancy complication occurrence using fetal cardiac output assessments made by ultrasonography at 20 to 24 weeks of gestation. *Obstet Gynecol Sci*. 2017; 60: 336-342.
7. Alkema L, Chou D, Hogan D, Zhang S, Moller A-B, Gemmill A, et al. Global, regional, and national levels and trends in maternal mortality between 1990 and 2015, with scenario-based projections to 2030: a systematic analysis by the UN Maternal Mortality Estimation Inter-Agency Group. *The Lancet*. 2016; 387: 462-474.
8. Knight M. UKOSS. Eclampsia in the United Kingdom 2005. *BJOG*. 2007; 114: 1072-1078.
9. Geographic variation in the incidence of hypertension in pregnancy. World Health Organization International Collaborative Study of Hypertensive Disorders of Pregnancy. *Am J Obstet Gynecol*. 1988; 158: 80-83.
10. Stone PJ, Franzblau C. Increase in urinary desmosine and pyridinoline during postpartum involution of the uterus in humans. *Proc Soc Exp Biol Med*. 1995; 210: 39-42.
11. Goel A, Maski MR, Bajracharya S, Wenger JB, Zhang D, Salahuddin S, et al. Epidemiology and Mechanisms of De Novo and Persistent Hypertension in the Postpartum Period. *Circulation*. 2015; 132: 1726-1733.
12. Bernstein PS, Martin JN, Barton JR, Shields LE, Druzin ML, Scavone BM, et al. National Partnership for Maternal Safety: Consensus Bundle on Severe Hypertension During Pregnancy and the Postpartum Period. *Obstet Gynecol*. 2017; 130: 347-357.
13. Committee on Obstetric Practice. Committee Opinion No. 692: Emergent Therapy for Acute-Onset, Severe Hypertension During Pregnancy and the Postpartum Period. *Obstet Gynecol*. 2017; 129: 90-95.
14. Vayssière C, Sentilhes L, Ego A, Bernard C, Cambourieu D, Flamant C, et al. Fetal growth restriction and intra-uterine growth restriction: guidelines for clinical practice from the French College of Gynaecologists and Obstetricians. *Eur J Obstet Gynecol Reprod Biol*. 2015; 193:10-18.
15. Duley L. The global impact of pre-eclampsia and eclampsia. *Semin Perinatol*. 2009; 33: 130-137.
16. Redline RW, Patterson P. Pre-eclampsia is associated with an excess of proliferative immature intermediate trophoblast. *Hum Pathol*. 1995; 26: 594-600.
17. Genbacev O, Joslin R, Damsky CH, Polliotti BM, Fisher SJ. Hypoxia alters early gestation human cytotrophoblast differentiation/invasion in vitro and models the placental defects that occur in preeclampsia. *J Clin Invest*. 1996; 97: 540-550.
18. Furuya M, Ishida J, Aoki I, Fukamizu A. Pathophysiology of placentation abnormalities in pregnancy-induced hypertension. *Vasc Health Risk Manag*. 2008; 4: 1301-1313.
19. Craici IM, Wagner SJ, Weissgerber TL, Grande JP, Garovic VD. Advances in the pathophysiology of pre-eclampsia and related podocyte injury. *Kidney Int*. 2014; 86: 275-285.
20. Saito S, Nakashima A. A review of the mechanism for poor placentation in early-onset preeclampsia: the role of autophagy in trophoblast invasion and vascular remodeling. *J Reprod Immunol*. 2014;101: 80-88.
21. Redman CW, Sargent IL, Staff AC. IFPA Senior Award Lecture: making sense of pre-eclampsia - two placental causes of preeclampsia? *Placenta*. 2014; 35: 20-25.
22. Barrientos G, Pussetto M, Rose M, Staff AC, Blois SM, Toblli JE. Defective trophoblast invasion underlies fetal growth restriction and preeclampsia-like symptoms in the stroke-prone spontaneously hypertensive rat. *Mol Hum Reprod*. 2017; 23: 509-519.
23. Verlohren S. Pre-eclampsia is primarily a placental disorder: FOR: Pre-eclampsia is primarily a placental disorder. *BJOG*. 2017; 124: 1762.
24. North RA, McCowan LME, Dekker GA, Poston L, Chan EHY, Stewart AW, et al. Clinical risk prediction for pre-eclampsia in nulliparous women: development of model in international prospective cohort. *BMJ*. 2011; 342: 1875.
25. Akolekar R, Syngelaki A, Poon L, Wright D, Nicolaides KH. Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. *Fetal Diagn Ther*. 2013; 33: 8-15.
26. Myers JE, Kenny LC, McCowan LME, Chan EHY, Dekker GA, Poston L, et al. Angiogenic factors combined with clinical risk factors to predict preterm pre-eclampsia in nulliparous women: a predictive test accuracy study. *BJOG*. 2013; 120: 1215-1223.
27. Saleh L, Vergouwe Y, van den Meiracker AH, Verdonk K, Russcher H, Bremer HA, et al. Angiogenic Markers Predict Pregnancy Complications and Prolongation in Preeclampsia: Continuous Versus Cutoff Values. *Hypertension*. 2017; 70: 1025-1033.
28. Al-Amin A, Rolnik DL, Black C, White A, Stolarek C, Brennecke S, et al. Accuracy of second trimester prediction of preterm preeclampsia by three different screening algorithms. *Aust N Z J Obstet Gynaecol*. 2017.
29. Prefumo F, Farina A. First-trimester screening for pre-eclampsia: time for reflection. *Ultrasound Obstet Gynecol*. 2017; 50: 662-663.
30. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. *Lancet*. 2010; 376: 631-644.
31. Poon LCY, Karagiannis G, Leal A, Romero XC, Nicolaides KH. Hypertensive disorders in pregnancy: screening by uterine artery Doppler imaging and blood pressure at 11-13 weeks. *Ultrasound Obstet Gynecol*. 2009; 34: 497-502.
32. Poon LC, Kametas NA, Chelemen T, Leal A, Nicolaides KH. Maternal risk factors for hypertensive disorders in pregnancy: a multivariate approach. *J Hum Hypertens*. 2010; 24: 104-110.
33. Martin A, Krishna I, Badell M, Samuel A. Can the quantity of cell-free fetal DNA predict preeclampsia: a systematic review. *Prenat Diagn*. 2014; 34: 685-691.
34. Anderson UD, Gram M, Åkerström B, Hansson SR. First trimester prediction of preeclampsia. *Curr Hypertens Rep*. 2015; 17: 584.
35. Park HJ, Shim SS, Cha DH. Combined Screening for Early Detection of Pre-Eclampsia. *Int J Mol Sci*. 2015; 16: 17952-17974.
36. Spencer K, Cowans NJ, Chefetz I, Tal J, Meiri H. First-trimester maternal serum PP-13, PAPP-A and second-trimester uterine artery Doppler pulsatility index as markers of pre-eclampsia. *Ultrasound Obstet Gynecol*. 2007; 29: 128-134.
37. Giguère Y, Charland M, Bujold E, Bernard N, Grenier S, Rousseau F, et al. Combining biochemical and ultrasonographic markers in predicting preeclampsia: a systematic review. *Clin Chem*. 2010; 56: 361-375.
38. Buurma AJ, Turner RJ, Driessen JHM, Mooyaart AL, Schoones JW, Bruijn JA, et al. Genetic variants in pre-eclampsia: a meta-analysis. *Hum Reprod Update*. 2013; 19: 289-303.
39. Fong FM, Sahemey MK, Hamed G, Eyitayo R, Yates D, Kuan V, et al. Maternal genotype and severe preeclampsia: a HuGE review. *Am J Epidemiol*. 2014; 180: 335-345.
40. Tjoa ML, Jani J, Lewi L, Peter I, Wataganara T, Johnson KL, et al. Circulating cell-free fetal messenger RNA levels after fetoscopic

- interventions of complicated pregnancies. *Am J Obstet Gynecol.* 2006; 195: 230-235.
41. Miranda ML, Macher HC, Muñoz-Hernández R, Vallejo-Vaz A, Moreno-Luna R, Villar J, et al. Role of circulating cell-free DNA levels in patients with severe preeclampsia and HELLP syndrome. *Am J Hypertens.* 2013; 26: 1377-1380.
42. Cotter AM, Martin CM, O'leary JJ, Daly SF. Increased fetal DNA in the maternal circulation in early pregnancy is associated with an increased risk of preeclampsia. *Am J Obstet Gynecol.* 2004; 191: 515-520.
43. Taglauer ES, Wilkins-Haug L, Bianchi DW. Review: cell-free fetal DNA in the maternal circulation as an indication of placental health and disease. *Placenta.* 2014; 35: 64-68.
44. Saraswathy S, Sahai K, Yadav TP, Arora D, Mendiratta SL, Naqvi SH, et al. Evaluation of fetal hypermethylated RASSF1A in pre-eclampsia and its relationship with placental protein-13, pregnancy associated plasma protein-A and urine protein. *Pregnancy Hypertens.* 2016; 6: 306-312.
45. Pineles BL, Romero R, Montenegro D, Tarca AL, Han YM, Kim YM, et al. Distinct subsets of microRNAs are expressed differentially in the human placentas of patients with preeclampsia. *Am J Obstet Gynecol.* 2007; 196: 261.
46. Zhu X, Han T, Sargent IL, Yin G, Yao Y. Differential expression profile of microRNAs in human placentas from preeclamptic pregnancies vs normal pregnancies. *Am J Obstet Gynecol.* 2009; 200: 661.
47. Enquobahrie DA, Abetew DF, Sorensen TK, Willoughby D, Chidambaram K, Williams MA. Placental microRNA expression in pregnancies complicated by preeclampsia. *Am J Obstet Gynecol.* 2011; 204:178.
48. Mayor-Lynn K, Toloubeydokhti T, Cruz AC, Chegini N. Expression profile of microRNAs and mRNAs in human placentas from pregnancies complicated by preeclampsia and preterm labor. *Reprod Sci.* 2011; 18: 46-56.
49. Wang W, Feng L, Zhang H, Hachy S, Satohisa S, Laurent LC, et al. Preeclampsia up-regulates angiogenesis-associated microRNA (i.e., miR-17, -20a, and -20b) that target ephrin-B2 and EPHB4 in human placenta. *J Clin Endocrinol Metab.* 2012; 97: 1051-1059.
50. Xu P, Zhao Y, Liu M, Wang Y, Wang H, Li YX, et al. Variations of microRNAs in human placentas and plasma from preeclamptic pregnancy. *Hypertension.* 2014; 63: 1276-1284.
51. Murphy MS, Casselman RC, Tayade C, Smith GN2. Differential expression of plasma microRNA in preeclamptic patients at delivery and 1 year postpartum. *Am J Obstet Gynecol.* 2015; 213: 367.
52. Zhang Y, Huang G, Zhang Y, Yang H, Long Y, Liang Q, et al. MiR-942 decreased before 20 weeks gestation in women with preeclampsia and was associated with the pathophysiology of preeclampsia in vitro. *Clin Exp Hypertens.* 2017; 39: 108-113.
53. Nanjo S, Minami S, Mizoguchi M, Yamamoto M, Yahata T, Toujima S1, et al. Levels of serum-circulating angiogenic factors within 1 week prior to delivery are closely related to conditions of pregnant women with pre-eclampsia... *J Obstet Gynaecol Res.* 2017; 43: 1805-1814.
54. Askie LM, Duley L, Henderson-Smart DJ, Stewart LA, PARIS Collaborative Group. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. *Lancet.* 2007; 369: 1791-1798.
55. Hofmeyr GJ, Belizán JM, von Dadelszen P; Calcium and Pre-eclampsia (CAP) Study Group. Low-dose calcium supplementation for preventing pre-eclampsia: a systematic review and commentary. *BJOG.* 2014; 121: 951-957.
56. Hofmeyr GJ, Seuc AH, Betrán AP, Purnat TD, Ciganda A, Munjanja SP, et al. The effect of calcium supplementation on blood pressure in non-pregnant women with previous pre-eclampsia: An exploratory, randomized placebo controlled study. *Pregnancy Hypertens.* 2015; 5: 273-279.
57. Redman CWG, Staff AC. Preeclampsia, biomarkers, syncytiotrophoblast stress, and placental capacity. *Am J Obstet Gynecol.* 2015; 213: 9-11.
58. Lokossou AG, Toudic C, Barbeau B. Implication of human endogenous retrovirus envelope proteins in placental functions. *Viruses.* 2014; 6: 4609-4627.
59. Kaitu'u-Lino TJ, Brownfoot FC, Hastie R, Chand A, Cannon P, Deo M, et al. Activating Transcription Factor 3 Is Reduced in Preeclamptic Placentas and Negatively Regulates sFlt-1 (Soluble fms-Like Tyrosine Kinase 1), Soluble Endoglin, and Proinflammatory Cytokines in Placenta. *Hypertension.* 2017; 70: 1014-1024.
60. Fu H, Wu W, Hu H, Liu X. [Effects of placental growth factor on the secretion of proinflammatory cytochemokines in vascular endothelial cells]. *Sichuan Da Xue Xue Bao Yi Xue Ban.* 2009; 40: 385-388.
61. Royle C, Lim S, Xu B, Tooher J, Ogle R, Hennessy A. Effect of hypoxia and exogenous IL-10 on the pro-inflammatory cytokine TNF-alpha and the anti-angiogenic molecule soluble Flt-1 in placental villous explants. *Cytokine.* 2009; 47: 56-60.
62. Knuth A, Liu L, Nielsen H, Merril D, Torrey DS, Arroyo JA. Placenta Growth Factor Induces Invasion and Activates p70 during Rapamycin Treatment in Trophoblast Cells. *Am J Reprod Immunol.* 2015; 73: 330-340.
63. Tsiakkas A, Duvdevani N, Wright A, Wright D, Nicolaidis KH. Serum placental growth factor in the three trimesters of pregnancy: effects of maternal characteristics and medical history. *Ultrasound Obstet Gynecol.* 2015; 45: 591-598.
64. Tsiakkas A, Mendez O, Wright A, Wright D, Nicolaidis KH. Maternal serum soluble fms-like tyrosine kinase-1 at 12, 22, 32 and 36 weeks' gestation in screening for pre-eclampsia. *Ultrasound Obstet Gynecol.* 2016; 47: 478-483.
65. Khalil A, Maiz N, Garcia-Mandujano R, Penco JM, Nicolaidis KH. Longitudinal changes in maternal serum placental growth factor and soluble fms-like tyrosine kinase-1 in women at increased risk of pre-eclampsia. *Ultrasound Obstet Gynecol.* 2016; 47: 324-331.
66. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, et al. Circulating angiogenic factors and the risk of preeclampsia. *N Engl J Med.* 2004; 350: 672-683.
67. Maynard SE, Min J-Y, Merchan J, Lim K-H, Li J, Mondal S, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. *J Clin Invest.* 2003; 111: 649-658.
68. Kar M. Role of biomarkers in early detection of preeclampsia. *J Clin Diagn Res.* 2014; 8: 1-4.
69. De Oliveira L, Peraçoli JC, Peraçoli MT, Korkeas H, Zampieri G, Moron AF, et al. sFlt-1/PlGF ratio as a prognostic marker of adverse outcomes in women with early-onset preeclampsia. *Pregnancy Hypertens.* 2013; 3: 191-195.
70. Wang A, Rana S, Karumanchi SA. Preeclampsia: the role of angiogenic factors in its pathogenesis. *Physiology (Bethesda).* 2009; 147-158.
71. Jantarasangaram S, Tansatit T, Samkhoopim N. PP178. Antenatal sFlt1 and PlGF levels at 20-28weeks of gestation for prediction of the occurrence of preeclampsia: A preliminary report. *Pregnancy Hypertens.* 2012; 2: 337.
72. Chelli D, Hamdi A, Saoudi S, Jenayah AA, Zagre A, Jguerim H, et

- al. Clinical Assessment of Soluble FMS-Like Tyrosine Kinase-1/Placental Growth Factor Ratio for the Diagnostic and the Prognosis of Preeclampsia in the Second Trimester. *Clin Lab*. 2016; 62: 1927-1932.
73. Vieira MC, Poston L, Fyfe E, Gillett A, Kenny LC, Roberts CT, et al. Clinical and biochemical factors associated with preeclampsia in women with obesity. *Obesity (Silver Spring)*. 2017; 460-467.
74. Zhou Y, McMaster M, Woo K, Janatpour M, Perry J, Karpanen T, et al. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. *Am J Pathol*. 2002; 160:1405-1423.
75. Bramham K, Seed PT, Lightstone L, Nelson-Piercy C, Gill C, Webster P, et al. Diagnostic and predictive biomarkers for pre-eclampsia in patients with established hypertension and chronic kidney disease. *Kidney Int*. 2016; 89: 874-885.
76. Acharya A. Promising biomarkers for superimposed pre-eclampsia in pregnant women with established hypertension and chronic kidney disease. *Kidney Int*. 2016; 89: 743-746.
77. Myatt L, Clifton RG, Roberts JM, Spong CY, Wapner RJ, Thorp JM, et al. Can changes in angiogenic biomarkers between the first and second trimesters of pregnancy predict development of pre-eclampsia in a low-risk nulliparous patient population? *BJOG Int J Obstet Gynaecol*. 2013; 120: 1183-1191.
78. Rana S, Karumanchi SA, Lindheimer MD. Angiogenic factors in diagnosis, management, and research in preeclampsia. *Hypertension*. 2014; 63: 198-202.
79. Henry-Berger J, Mouzat K, Baron S, Bernabeu C, Marceau G, Saru J-P, et al. Endoglin (CD105) expression is regulated by the liver X receptor alpha (NR1H3) in human trophoblast cell line JAR. *Biol Reprod*. 2008; 78: 968-975.
80. Plösch T, Gellhaus A, van Straten EM, Wolf N, Huijkman NC, Schmidt M, et al. The liver X receptor (LXR) and its target gene ABCA1 are regulated upon low oxygen in human trophoblast cells: a reason for alterations in preeclam. *Placenta*. 2010; 31: 910-918.
81. Weedon-Fekj r MS, Johnsen GM, Anthonisen EH, Sugulle M, Nebb HI, Duttaroy AK, et al. Expression of liver X receptors in pregnancies complicated by preeclampsia. *Placenta*. 2010; 31: 818-824.
82. Bell MJ, Conley YP. A systematic review of endoglin gene expression in preeclampsia. *Biol Res Nurs*. 2013; 15: 129-136.
83. Bell MJ, Roberts JM, Founds SA, Jayabalan A, Terhorst L, Conley YP. Variation in endoglin pathway genes is associated with preeclampsia: a case-control candidate gene association study. *BMC Pregnancy Childbirth*. 2013; 13: 82.
84. Burke KT, Colvin PL, Myatt L, Graf GA, Schroeder F, Woollett LA. Transport of maternal cholesterol to the fetus is affected by maternal plasma cholesterol concentrations in the golden Syrian hamster. *J Lipid Res*. 2009; 50: 1146-1155.
85. Mano Y, Kotani T, Shibata K, Matsumura H, Tsuda H, Sumigama S, et al. The loss of endoglin promotes the invasion of extravillous trophoblasts. *Endocrinology*. 2011; 152: 4386-4394.
86. Wang J, Dong X2, Wu HY, Wu N, Zhang XJ, Wang X1, et al. Relationship of Liver X Receptors α and Endoglin Levels in Serum and Placenta with Preeclampsia. *PLoS One*. 2016; 13: 11.
87. Lawrence JB, Oxvig C, Overgaard MT, Sottrup-Jensen L, Gleich GJ, Hays LG, et al. The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A. *Proc Natl Acad Sci U S A*. 1999; 96: 3149-3153.
88. Than NG, Romero R, Kim CJ, McGowen MR, Papp Z, Wildman DE. Galectins: guardians of eutherian pregnancy at the maternal-fetal interface. *Trends Endocrinol Metab*. 2012; 23: 23-31.
89. Carty DM, Delles C, Dominiczak AF. Novel biomarkers for predicting preeclampsia. *Trends Cardiovasc Med*. 2008; 18: 186-194.
90. Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P, Canadian Hypertensive Disorders of Pregnancy Working Group. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary. *J Obstet Gynaecol*. 2014; 36: 416-441.
91. Polsani S, Phipps E, Jim B. Emerging new biomarkers of preeclampsia. *Adv Chronic Kidney Dis*. 2013; 20: 271-279.
92. Bersinger NA, Sm rason AK, Muttukrishna S, Groome NP, Redman CW. Women with preeclampsia have increased serum levels of pregnancy-associated plasma protein A (PAPP-A), inhibin A, activin A and soluble E-selectin. *Hypertens Pregnancy*. 2003; 22: 45-55.
93. Bersinger NA, Ødegård RA. Second- and third-trimester serum levels of placental proteins in preeclampsia and small-for-gestational age pregnancies. *Acta Obstet Gynecol Scand*. 2004; 83: 37-45.
94. Deveci K, Sogut E, Evliyaoglu O, Duras N. Pregnancy-associated plasma protein-A and C-reactive protein levels in pre-eclamptic and normotensive pregnant women at third trimester. *J Obstet Gynaecol Res*. 2009; 35: 94-98.
95. Huppertz B. Placental origins of preeclampsia: challenging the current hypothesis. *Hypertens Dallas Tex* 1979. 2008; 51: 970-975.
96. Huppertz B, Sammar M, Chefetz I, Neumaier-Wagner P, Bartz C, Meiri H. Longitudinal determination of serum placental protein 13 during development of preeclampsia. *Fetal Diagn Ther*. 2008; 24: 230-236.
97. Gonen R, Shahar R, Grimpel YI, Chefetz I, Sammar M, Meiri H, et al. Placental protein 13 as an early marker for pre-eclampsia: a prospective longitudinal study. *BJOG Int J Obstet Gynaecol*. 2008; 115: 1465-1472.
98. Yildirim ZK, Sumnu A, Bademler N, Kilic E, Sumnu G, Karadag S, et al. Soluble TNF-Like Weak Inducer of Apoptosis as a New Marker in Preeclampsia: A Pilot Clinical Study. *Dis Markers*. 2016; 2016: 5930589.
99. Matthiesen L, Berg G, Ernerudh J, Ekerfelt C, Jonsson Y, Sharma S. Immunology of preeclampsia. *Chem Immunol Allergy*. 2005; 89: 49-61.
100. Siwetz M, Dieber-Rotheneder M, Cervar-Zivkovic M, Kummer D, Kremshofer J, Weiss G, et al. Placental fractalkine is up-regulated in severe early-onset preeclampsia. *Am J Pathol*. 2015; 185:1334-1343.
101. Rusterholz C, Hahn S, Holzgreve W. Role of placentally produced inflammatory and regulatory cytokines in pregnancy and the etiology of preeclampsia. *Semin Immunopathol*. 2007; 29: 151-162.
102. Messerli M, May K, Hansson SR, Schneider H, Holzgreve W, Hahn S, et al. Feto-maternal interactions in pregnancies: placental microparticles activate peripheral blood monocytes. *Placenta*. 2010; 31: 106-112.
103. Redman CW, Tannetta DS, Dragovic RA, Gardiner C, Southcombe JH, Collett GP, et al. Review: Does size matter? Placental debris and the pathophysiology of pre-eclampsia. *Placenta*. 2012; 33: 48-54.
104. Al-oi E, Coffelt SB, Anumba DO. Monocyte subpopulations from pre-eclamptic patients are abnormally skewed and exhibit exaggerated responses to Toll-like receptor ligands. *PLoS One*. 2012; 7:42217.
105. Lee SM, Romero R, Lee YJ, Park IS, Park C-W, Yoon BH. Systemic inflammatory stimulation by microparticles derived from hypoxic trophoblast as a model for inflammatory response in preeclampsia. *Am J Obstet Gynecol*. 2012; 207: 337.

106. Raghupathy R. Cytokines as key players in the pathophysiology of preeclampsia. *Med Princ Pract*. 2013; 22: 8-19.
107. Liu X, Dai LI, Zhou R. Association between preeclampsia and the CXC chemokine family (Review). *Exp Ther Med*. 2015; 9: 1572-1576.
108. Molvarec A, Czeglé I, Szijrt J, Rig J. Increased circulating interleukin-17 levels in preeclampsia. *J Reprod Immunol*. 2015; 112: 53-57.
109. Liu L, Han X, Huang Q, Zhu X, Yang J, Liu H. Increased neuronal seizure activity correlates with excessive systemic inflammation in a rat model of severe preeclampsia. *Hypertens Res Off J Jpn Soc Hypertens*. 2016; 39: 701-708.
110. Al-Ofi EA, Anumba DO. Ligands of toll-like receptors 2/4 differentially alter markers of inflammation, adhesion and angiogenesis by monocytes from women with pre-eclampsia in co-culture with endothelial cells. *J Reprod Immunol*. 2017; 121: 26-33.
111. Mangeney M, Renard M, Schlecht-Louf G, Bouallaga I, Heidmann O, Letzelter C, et al. Placental syncytins: Genetic disjunction between the fusogenic and immunosuppressive activity of retroviral envelope proteins. *Proc Natl Acad Sci U S A*. 2007; 104: 20534-20539.
112. Schlecht-Louf G, Renard M, Mangeney M, Letzelter C, Richaud A, Ducos B, et al. Retroviral infection in vivo requires an immune escape virulence factor encrypted in the envelope protein of oncoretroviruses. *Proc Natl Acad Sci U S A*. 2010; 107: 3782-3787.
113. Toufaily C, Lokossou AG, Vargas A, Rassart É, Barbeau B. A CRE/AP-1-like motif is essential for induced syncytin-2 expression and fusion in human trophoblast-like model. *PLoS One*. 2015; 10: 0121468.
114. Kshirsagar SK, Alam SM, Jasti S, Hodes H, Nauser T, Gilliam M, et al. Immunomodulatory molecules are released from the first trimester and term placenta via exosomes. *Placenta*. 2012; 33: 982-990.
115. Vargas A, Zhou S, thier-Chiasson M, Flipo D, Lafond J, Gilbert C, et al. Syncytin proteins incorporated in placenta exosomes are important for cell uptake and show variation in abundance in serum exosomes from patients with preeclampsia. *FASEB J Off Publ Fed Am Soc Exp Biol*. 2014; 28: 3703-3719.
116. Karampas GA, Eleftheriades MI, Panoulis KC, Rizou MD, Haliassos AD, Metallinou DK, et al. Prediction of pre-eclampsia combining NGAL and other biochemical markers with Doppler in the first and/or second trimester of pregnancy. A pilot study. *Eur J Obstet Gynecol Reprod Biol*. 2016; 205: 153-157.
117. Chang Y, Chen X, Cui H-Y, Li X, Xu Y-L. New Predictive Model at 11(+0) to 13(+6) Gestational Weeks for Early-Onset Preeclampsia With Fetal Growth Restriction. *Reprod Sci Thousand Oaks Calif*. 2017; 24: 783-789.

Cite this article

Lokossou GAG, Toudic C, Lozes EJ, Davito L, Badarou AA, et al. (2018) Preeclampsia: Where do we stand for an Early Diagnosis? *Med J Obstet Gynecol* 6(1): 1113.